Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera Inc (NASDAQ: NTRA) delivers cutting-edge genetic testing solutions through its proprietary molecular diagnostics platform. This news hub provides investors and healthcare professionals with timely updates on corporate developments, clinical research breakthroughs, and regulatory milestones.
Access official press releases alongside curated analysis of NTRA's innovations in non-invasive prenatal testing, oncology diagnostics, and transplant monitoring. Our repository tracks critical updates including quarterly earnings, partnership announcements, and peer-reviewed study publications.
Key coverage areas include advancements in circulating tumor DNA detection, expansions in reproductive health screening, and financial performance metrics. Bookmark this page to monitor how Natera's bioinformatics expertise continues influencing precision medicine across 150+ countries.
Natera (NASDAQ: NTRA) announced a study published in Annals of Oncology demonstrating its ctDNA assay, Signatera, can effectively monitor neoadjuvant chemotherapy (NAC) responses in breast cancer patients. The study involved 291 plasma samples from 84 patients, revealing that early ctDNA clearance is significantly associated with achieving pathologic complete response (pCR), which indicates better survival outcomes. The findings suggest Signatera could improve treatment decisions and outcomes for breast cancer patients, particularly in predicting metastatic recurrence.
Natera, Inc. (NASDAQ: NTRA) has appointed Dr. Monica Bertagnolli to its board of directors. Dr. Bertagnolli, a renowned oncology researcher and professor at Harvard Medical School, brings extensive clinical experience to the role. CEO Steve Chapman expressed confidence in her ability to drive the company’s vision of advancing MRD testing as a standard of care. Dr. Bertagnolli's involvement is expected to enhance Natera's innovation in ctDNA technology, particularly in the application of Signatera technology, which aims to improve patient outcomes in oncology.
Natera, Inc. (NASDAQ: NTRA) announced a live webcast presentation at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 1:30 p.m. PT (4:30 p.m. ET). Mike Brophy, Chief Financial Officer, will discuss the company's latest developments. The webcast will be accessible live and archived on investor.natera.com.
Natera, a leader in cell-free DNA testing, aims to transform disease management, focusing on women’s health, oncology, and organ health.
Natera, Inc. (NASDAQ: NTRA) announced new data for its personalized molecular residual disease assay, Signatera, at the SITC 35th Annual Meeting, held from November 9-14, 2020. The presentations highlighted Signatera's capability in monitoring immunotherapy responses in colorectal and breast cancer. Key findings included early detection of treatment response dynamics via circulating tumor DNA (ctDNA) analyses, demonstrating the assay's utility in clinical decision-making and the monitoring of treatment efficacy.
Natera (NASDAQ: NTRA) reported strong Q3 2020 results with total revenues of $98.1 million, a 26% increase from Q3 2019, driven by a 39.5% rise in product revenues. The company processed 262,000 tests, up 31% year-over-year. Gross profit reached $46.3 million with a 47% gross margin. However, operating expenses grew to $102.1 million, leading to a net loss of $58.3 million, or ($0.72) per share. Natera raised its 2020 revenue guidance, expecting $380 million to $390 million in total revenues.
Natera, a leader in cell-free DNA testing, welcomes the ISPD's position statement endorsing cfDNA screening for twin pregnancies. This backing reinforces the clinical value of Non-Invasive Prenatal Testing (NIPT) for identifying autosomal trisomies. The statement emphasizes the importance of incorporating zygosity in NIPT interpretation, highlighting Natera's Panorama test's unique capability to assess zygosity and fetal fractions. This endorsement positions Natera favorably to expand its market leadership in NIPT.
Natera, a leader in cell-free DNA testing, is set to release its third quarter 2020 financial results on November 5, 2020, after market close. The company will hold a conference call at 1:30 PM PT to discuss these results, along with business activities and future outlook. Interested parties can join via live dial-in or webcast. Natera aims to transform disease management in women's health, oncology, and organ health, leveraging its innovative genetic testing services and cloud-based platform.
Natera, Inc. (NASDAQ: NTRA) announces the extension of non-invasive prenatal testing (NIPT) coverage for all singleton pregnancies by a major health plan, adding 17 million covered lives. This extends the total to 139 million commercial lives, representing approximately 77% of total lives covered for average risk NIPT in the U.S. This expansion aligns with new ACOG guidelines supporting NIPT, aiming to unlock volume growth in a currently underpenetrated market. Natera emphasizes its Panorama® test's advanced SNP-based technology and its extensive clinical evidence to support this growth.
Natera, Inc. (NASDAQ: NTRA) announced it will present new data at the 2020 American Society of Nephrology (ASN) Kidney Week virtual meeting from October 22-25. The presentations will focus on the Prospera test, demonstrating its efficacy in patients with second kidney transplants and those affected by COVID-19 or other viral infections. Key findings indicate significant differences in donor-derived cell-free DNA (dd-cfDNA) levels between rejection and non-rejection cases. These insights aim to enhance understanding of kidney transplant rejection across patient demographics.
Natera, Inc. (NASDAQ: NTRA) announced that Centene has extended coverage for its Panorama non-invasive prenatal test (NIPT) to all pregnant women, including those with twins, impacting 24 million additional covered lives. The extension follows ACOG and SMFM's new guidelines supporting NIPT for all patients, regardless of age or risk. Natera's General Manager highlighted the significant growth potential in the under-penetrated average risk NIPT market due to expanded insurance coverage. Panorama is the only NIPT that differentiates between maternal and fetal DNA, analyzing risks for genetic disorders as early as nine weeks into pregnancy.
